Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABP 234 vs Pembrolizumab in Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Sep 2024
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of abp 234 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Amgen. Primary endpoints: Area under the serum concentration-time curve from time 0 to 21 days and Area under the serum concentration-time curve at steady state. Started Sep 2024; status: active, not recruiting.
02
Drugs
abp 234
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06311721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311721.